---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-026335"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2024-07-05T23:59:59+00:00"
generated_at: "2026-05-31T23:21:33.105300+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Oncocyte annual meeting elects directors, ratifies auditor; Board confirms Arno independence

## Summary
- Shareholders elected four director nominees (Riggs, Arno, Last, Silverman) with ~7.98M votes each; quorum 81.5%.
- Ratified Marcum LLP as auditor for FY2024: 10.8M for, 10.9k against, 11k abstain.
- Approved non-binding say-on-pay proposal: 8.12M for, 20k against, 11k abstain.
- Board determined Andrew Arno independent per Nasdaq rules as of July 1, 2024; Arno chairs Compensation, Last chairs Audit, Silverman chairs Nominating.

## SEC filing metadata
- accession: 0001493152-24-026335
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2024-07-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.07, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315224026335/0001493152-24-026335-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315224026335/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-026335
- JSON: https://secwatch.observer/filing/0001493152-24-026335.json
- Plain text: https://secwatch.observer/filing/0001493152-24-026335.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.